| Platforms for Myeloma Disease Evaluation |
P-selectin-targeted therapies can aid in delivery of agents to the bone marrow microenvironment (Azab) MALDI-TOF can detect small monoclonal proteins in patients considered to have oligo-secretory or non-secretory disease (Giles) Daratumumab radio-labeled antibodies have diagnostic and therapeutic potential (Pichiorri) Immuno-PET imaging may be a promising strategy for stratifying patients for immune- and cell-based therapy (Shokeen)
|
| Insights into Pathogenesis |
The tumor matrix proteoglycan versican modulates the immune microenvironment (Asimakopoulos) Chromothripsisis is associated with progression in myeloma precursors (Maclachlan) Inflammatory mesenchymal stromal cells could be myeloma niche cells and their presence is associated with bone marrow inflammation (Cupedo) Focal lesions are hotspots for genetic and transcriptional heterogeneity (John)
|
| Therapeutic Targets & Resistance Mechanisms |
Regional copy loss of CRBN at 3p and COPS7b/8 at 2q37 may mediate IMiD resistance (Gooding) Inhibition of IRF4 represents a novel therapeutic strategy (Crews) Resistance to CD3-directed bispecific antibodies is likely a combination of intrinsic and acquired mechanisms, including tumor-dependent and T-cell/tumor microenvironment-dependent mechanisms (Verona) HDAC3 may be a promising target to block the bone marrow niche-myeloma interaction and limit myeloma cell survival (Bianchi)
|
| Cellular Therapy |
Early clearance of soluble BCMA correlates with durable responses in patients who received idecabtagene vicleucel in the KarMMa trial (Kaiser) Non-viral knockin strategies using single stranded DNA can be applied to BCMA CAR T-cell manufacturing (Shy) CAR T-cells targeting GPRC5D +/− BCMA appear promising (Smith) Studies evaluating CAR T-cells targeting APRIL have been disappointing and may be a reflection of differences between the natural ligand interaction and that required for CAR activation (Lee)
|
